Triphendiol (NV-196), development of a novel therapy for pancreatic cancer

Anti-Cancer Drugs

Volumn 22, Issue 8, 2011, Pages 719-731

  Wang, Xiaohong ^a   McKernan, Robert ^b   Kim, Ki H ^c   Alvero, Ayesha B ^c   Whiting, Ainslie ^b   Thompson, John Anthony ^a   Mor, Gil ^c   Saif, Muhammad Wasif ^d,g   Husband, Alan J ^b,e   Brown, David M ^b   Tytler, Ewan Milne ^a,f  

^a UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^b Department of Obstetrics and Gynecology ^*  (United States)

^c YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d Marshall Edwards Inc   (United States)

^e UNIVERSITY OF SYDNEY   (Australia)

^f Birmingham Campus   (United Kingdom)

^g Milstein Hospital   (United States)

Author keywords

apoptosis; cell cycle; gemcitabine; isoflavone; mitochondria; pancreatic cancer

Indexed keywords

ANTINEOPLASTIC AGENT; CASPASE; CASPASE INHIBITOR; DEATH RECEPTOR; GEMCITABINE; ISOFLAVONE DERIVATIVE; NV 196; PROTEIN P53; TRIPHENDIOL; UNCLASSIFIED DRUG;

ADVANCED CANCER; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CELL ACTIVATION; CELL CYCLE ARREST; CELL CYCLE G2 PHASE; CELL CYCLE M PHASE; CELL DEATH; CELL PROLIFERATION; CONTROLLED STUDY; CYTOTOXICITY; DRUG ACTIVITY; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; DRUG EFFICACY; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IN VITRO STUDY; MALE; MITOCHONDRION; MONOTHERAPY; MOUSE; NECROSIS; NONHUMAN; PANCREAS CANCER; PRIORITY JOURNAL; TUMOR XENOGRAFT; WESTERN BLOTTING;

ADENOCARCINOMA; ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; BLOTTING, WESTERN; CASPASES; CELL LINE, TUMOR; CELL PROLIFERATION; DEOXYCYTIDINE; DRUG EVALUATION, PRECLINICAL; FLOW CYTOMETRY; HUMANS; ISOFLAVONES; MALE; MICE; MICE, INBRED BALB C; MICE, NUDE; PANCREATIC NEOPLASMS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 80051546995     PISSN: 09594973     EISSN: 14735741     Source Type: Journal    
DOI: 10.1097/CAD.0b013e328346f3b4     Document Type: Article

References (45)

1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ. Cancer statistics. CA Cancer J Clin 2009; 59:225-249.
2. Hart AR, Kennedy H, Harvey I. Pancreatic cancer: a review of the evidence on causation. Clin Gastroenterol Hepatol 2008; 6:275-282. (Pubitemid 351318383)
3. Burris HA III, Moore MJ, Andersen J, Green MR, Rothenberg ML, Modiano MR, et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol 1997; 15:2403-2413. (Pubitemid 27251144)
4. Ishii H, Furuse J, Nagase M, Yoshino M. Impact of gemcitabine on the treatment of metastatic pancreatic cancer. J Gastroenterol Hepatol 2005; 20:62-66. (Pubitemid 40143635)
5. Tingstedt B, Johansson P, Andersson B, Andersson R. Predictive factors in pancreatic ductal adenocarcinoma: role of the inflammatory response. Scand J Gastroenterol 2007; 42:754-759. (Pubitemid 46763583)
6. Kang SP, Saif MW. Optimal second-line treatment options for gemcitabine refractory advanced pancreatic cancer patients: can we establish standard of care with available data? J Oral Pathol 2008; 9:83-90. (Pubitemid 351611723)
7. Hui YF, Reitz J. Gemcitabine: a cytidine analogue active against solid tumors. Am J Health Syst Pharm 1997; 54:162-170. (Pubitemid 27058210)
8. Schniewind B, Christgen M, Kurdow R, Haye S, Kremer B, Kalthoff H, et al. Resistance of pancreatic cancer to gemcitabine treatment is dependent on mitochondria-mediated apoptosis. Int J Cancer 2004; 109:182-188. (Pubitemid 38240918)
9. Arlt A, Gehrz A, Mü erkö ster S, Vorndamm J, Kruse M-L, Fö lsch UR, et al. Role of NF-kB and Akt/PI3K in the resistance of pancreatic carcinoma cell lines against gemcitabine-induced cell death. Oncogene 2003; 22: 3243-3251. (Pubitemid 36712936)
10. Xu Z-W, Friess H, Solioz M, Aebi S, Korc M, Kleef J, et al. Bcl-x(L) antisense oligonucleotides induce apoptosis and increase sensitivity of pancreatic cancer cells to gemcitabine. Int J Cancer 2001; 94:268-274. (Pubitemid 32911423)
11. Ng SSW, Tsao M-S, Chow S, Hedley DW. Inhibition of phosphatidylinositide 3-kinase enhances gemcitabine-induced apoptosis in human pancreatic cancer cells. Cancer Res 2000; 60:5451-5455.
12. Liau SS,Whang E. HMGA1 is a molecular determinant of chemoresistance to gemcitabine in pancreatic adenocarcinoma. Clin Cancer Res 2008; 14:1470-1477.
13. Duxbury MS, Ito H, Zinner MJ, Ashley SW, Whang EE. Inhibition of SRC tyrosine kinase impairs inherent and acquired gemcitabine resistance in human pancreatic adenocarcinoma cells. Clin Cancer Res 2004; 10:2307-2318. (Pubitemid 38445688)
14. Sebastiani V, Ricci F, Rubio-Viqueira B, Kulesza P, Yeo CJ, Hidalgo M, et al. Immunohistochemical and genetic evaluation of deoxycytidine kinase in pancreatic cancer: relationship to molecular mechanisms of gemcitabine resistance and survival. Clin Cancer Res 2006; 12:2492-2497.
15. Oettle H, Post S, Neuhaus P, Gellert K, Langrehr J, Ridwelski K, et al. Adjuvant chemotherapy with gemcitabine versus observation in patients undergoing curative-intent resection of pancreatic cancer: a randomized controlled trial. JAMA 2007; 297:267-277. (Pubitemid 46143304)
16. Alvero AB, O'Malley D, Brown D, Kelly G, Garg M, Chen W, et al. Molecular mechanism of phenoxodiol-induced apoptosis in ovarian carcinoma cells. Cancer 2006; 106:599-608. (Pubitemid 43157623)
17. Alvero AB, Brown D, Montagna M, Matthews M, Mor G. Phenoxodiol-topotecan co-administration exhibit significant anti-tumor activity without major adverse side effects. Cancer Biol Ther 2007; 6:612-617. (Pubitemid 47328337)
18. Sapi E, Alvero AB, Chen W, O'Malley D, Hao XY, Dwipoyono B, et al. Resistance of ovarian carcinoma cells to docetaxel is XIAP dependent and reversible by phenoxodiol. Oncol Res 2004; 14:567-578. (Pubitemid 40178958)
19. Kamsteeg M, Rutherford T, Sapi E, Hanczaruk B, Shahabi S, Flick M, et al. Phenoxodiol: an isoflavone analog-induces apoptosis in chemoresistant ovarian cancer cells. Oncogene 2003; 22:2611-2620. (Pubitemid 36605609)
20. Ahn E-Y, Pan G, Oh JH, Tytler EM, McDonald JM. The combination of calmodulin antagonists and interferon-g induces apoptosis through caspase-dependent and-independent pathways in cholangiocarcinoma cells. Am J Pathol 2003; 163:2053-2063. (Pubitemid 37310035)
21. Krumschnabel G, Sohm B, Bock F, Manzl C, Villunger A. The enigma of caspase-2: the laymen's view. Cell Death Differ 2009; 16: 195-207.
22. Deveraux QL, Takahashi R, Salvesen GS, Reed JC. X-linked IAP is a direct inhibitor of cell-death proteases. Nature 1997; 388:300-304. (Pubitemid 27317977)
23. Alvero AB, Montagna MK, Chen R, Kim KH, Kyungjin K, Visintin I, et al. NV-128, a novel isoflavone derivative, induces caspase-independent cell death through the Akt/mammalian target of rapamycin pathway. Cancer 2009; 115:3204-3216.
24. Bullock AN, Henckel J, Fersht AR. Quantitative analysis of residual folding and DNA binding in mutant p53 core domain: definition of mutant states for rescue in cancer therapy. Oncogene 2000; 19:1245-1256. (Pubitemid 30160617)
25. Chou TC, Talalay P. Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul 1984; 22:27-55.
26. Moore PS, Sipos B, Orlandini S, Sorio C, Real FX, Lemoine NR, et al. Genetic profile of 22 pancreatic carcinoma cell lines: analysis of K-ras, p53, p16 and DPC4/Smad4. Virchows Arch 2001; 439:798-802. (Pubitemid 33141325)
27. Kroemer G, Martin SJ. Caspase-independent cell death. Nature (Medicine) 2005; 11:725-730. (Pubitemid 41021204)
28. Saif MW, Tytler E, Lansigan F, Brown DM, Husband AJ. Flavonoids, phenoxodiol, and a novel agent, triphendiol, for the treatment of pancreaticobiliary cancers. Expert Opin Investigational Drugs 2009; 18:469-479.
29. Tinel A, Tschopp J. The PIDDosome, a protein complex implicated in activation of caspase-2 in response to genotoxic stress. Science 2004; 304:843-846. (Pubitemid 38620177)
30. Rö dicker F, Pü tzer BM. p73 is effective in p53-null pancreatic cancer cells resistant to wild-type TP53 gene replacement. Cancer Res 2003; 63:2737-2741. (Pubitemid 36667142)
31. Aguero MF, Facchinetti MM, Sheleg Z, Senerowicz AM. Phenoxodiol, a novel isoflavone, induces G1 arrest by specific loss in cyclin-dependent kinase 2 activity by p53-independent induction of p21WAF1/CIP1. Cancer Res 2005; 65:3364-3373. (Pubitemid 40524621)
32. Hu YX, Watanabe H, Ohtsubo K, Yamaguchi Y, Ha A, Motoo Y, et al. Infrequent expression of p21 is related to altered p53 protein in pancreatic carcinoma. Clin Cancer Res 1998; 4:1147-1152. (Pubitemid 28213324)
33. Zupanska A, Adach A, Dziembowska M, Kaminska B. Alternative pathway of transcriptional induction of p21WAF1/Cip1 by cyclosporine A in p53-deficient human glioblastoma cells. Cell Signal 2007; 19:1268-1278. (Pubitemid 46561563)
34. Rocco JW, Leong C-O, Kuperwasser N, DeYoung MP, Ellisen LW. p63 mediates survival in squamous cell carcinoma by suppression of p73-dependent apoptosis. Cancer Cell 2006; 9:45-56. (Pubitemid 43069510)
35. Kluger HM, McCarthy MM, Alvero AB, Sznol M, Ariyan S, Camp RL, et al. The X-linked inhibitor of apoptosis protein (XIAP) is up-regulated in metastatic melanoma, and XIAP cleavage by Phenoxodiol is associated with carboplatin sensitization. J Transl Med 2007; 5:6.
36. Kurdow R, Schniewind B, Zoefelt S, Boenicke L, Boehle AS, Dohrmann P, et al. Apoptosis by gemcitabine in non-small cell lung cancer cell line KNS62 is induced downstream of caspase 8 and is profoundly blocked by Bcl-xL over-expression. Langenbecks Arch Surg 2005; 390:243-248. (Pubitemid 40884235)
37. Boeck S, Wilkowski R, Bruns CJ, Issels RD, Schulz C, Moosmann N, et al. Oral capecitabine in gemcitabine-pretreated patients with advanced pancreatic cancer. Oncology 2007; 73:221-227. (Pubitemid 351630054)
38. Endlicher E, Troppmann M, Kullmann A, Golder S, Herold T, Herfarth H, et al. Irinotecan plus gemcitabine and 5-fluorouracil in advanced pancreatic cancer: a phase II study. Oncology 2007; 72:279-284. (Pubitemid 351238138)
39. Heinemann V, Quietzsch D, Gieseler F, Gonnermann M, Schö nekä s H, Rost A, et al. Randomized phase III trial of gemcitabine plus cisplatin compared with gemcitabine alone in advanced pancreatic cancer. J Clin Oncol 2006; 24:3946-3952. (Pubitemid 46630743)
40. Louvet C, Labianca R, Hammel P, Lledo G, Zampino MG, André T, et al. GERCOR; GISCAD: gemcitabine in combination with oxaliplatin compared with gemcitabine alone in locally advanced or metastatic pancreatic cancer: results of a GERCOR and GISCAD phase III trial. J Clin Oncol 2005; 23:3509-3516.
41. Kindler HL, Niedzwiecki D, Hollis D, Oraefo E, Schrag D, Hurwitz H, et al. A double-blind, placebo-controlled, randomized phase III trial of gemcitabine (G) plus bevacizumab (B) versus gemcitabine plus placebo (P) in patients (pts) with advanced pancreatic cancer (PC): a preliminary analysis of Cancer and Leukemia Group B (CALGB) 80303. J Clin Oncol 2007; (Suppl 18):4508.
42. Philip PA, Benedetti J, Fenoglio-Preiser C, Zalupski M, Lenz H, O'Reilly E, et al. Phase III study of gemcitabine [G] plus cetuximab [C] versus gemcitabine in patients [pts] with locally advanced or metastatic pancreatic adenocarcinoma [PC]: SWOG S0205 study. J Clin Oncol 2007; (Suppl 18):LBA4509.
43. Moore MJ, Goldstein D, Hamm J, Figer A, Hecht JR, Gallinger S, et al. Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 2007; 25: 1960-1966. (Pubitemid 46972777)
44. Saif MW. Erlotinib: the first biologic in the management of pancreatic cancer. Expert Opin Pharmacother 2008; 9:1595-1607.
45. Mainwaring PN,West L, Husband AJ. Phase 1a safety and pharmacokinetic study of oral NV-196 in patients with solid tumours. J Clin Oncol 2008; 26 (Suppl 15):abstr 14615.